After years of resistance, the health care and pharmaceutical industries are now accelerating full steam towards the cloud. In fact, the global health care cloud computing market, valued at $4.5 billion in 2016, will reach $9.5 billion by 2020. Here are the dominant benefits that are drawing these giants to the cloud.
When it comes to manoeuvrability and nimble response, large companies have more in common with ocean liners than speedboats. Policies are agreed, marketing strategies planned, and future developments or projects set in motion months or years in advance.
One healthcare official told me yesterday, 'Yes, drug prices need to come down. At the same time, though, we do need to ensure that pharma companies do keep the incentive to innovate.' And I've got the boss of one of the biggest healthcare companies in the world sitting right next to me, that's Joe Jimenez the CEO of Novartis.
The field of clinical research is growing and advancing thanks to technological advances like real time data collection and analysis, health care applications, and wearable technologies. The clinical trial industry is seeing huge strides thanks to these digital and technological advances that are making studies more efficient, faster, safer, and garnering more participants
The melanoma pipeline, which is typically underserved due to stubborn R&D challenges, is being praised for its levels of innovation as of late with 579 programs active across all stages of development, with 226 first-in-class programs in the pipeline, acting on 138 distinct first-in-class molecular targets. This accounts for 38% of all programs with a disclosed molecular target and reflects the high degree of innovation in this indication, according to business intelligence provider GBI Research.
At the start of 2016, the industry predicted many market access trends. As we come to the end of the year, let us look at the market access trends predicted at the start of 2016. How have these predictions unfolded so far and what will be the next set of trends for the coming year?
With several patent expiries in 2015 and 2016, there was high expectation that a significant portion of the biologics market would shift to biosimilar use by 2016, especially in the areas of diabetes, rheumatology, and in tendering markets. I
2017 is set to be an exciting time for pharma companies to develop and adopt new strategies and models to stay ahead of both the expected and unexpected market trends.
Health experts and medical personnel will be the first to say that the medical field is lagging behind when it comes to technology and innovation.
The last quarter of 2016 was certainly not short of activity with a £84 million pharma fine issued in regards to drug pricings, an investigation into a suspected supply chain breach and numerous therapeutic approvals.